Red flags in the cosmetic peptide market — fake melanotan, mislabeled GHK-Cu, topical absorption myths

The cosmetic peptide market has its own specific scam patterns that differ from the medicinal peptide categories. The compounds are marketed more aggressively to consumers (rather than to research-framed buyers), the topical formulation space adds quality issues that injectables do not have, and the melanotan and copper peptide families each have their own substitution problems. This thread covers the specific patterns to watch for.

Pattern 1: The melanotan I versus melanotan II ambiguity.
Some vendors sell "melanotan" without specifying whether it is melanotan I or melanotan II. The two compounds have different receptor selectivity profiles (melanotan I more selective for MC1R, melanotan II non-selective across MC1R/MC3R/MC4R/MC5R) and produce different effect and side effect profiles. A buyer who has been studying melanotan I for pigmentation effects and switches to a vendor selling unspecified "melanotan" may receive melanotan II — and the broader receptor activation produces appetite suppression, sexual function changes, and other effects that were not part of the original research design.

How to detect it: refuse to buy any melanotan product that does not explicitly specify I or II. Mass spec on the COA will distinguish them (1646.85 Da for melanotan I, 1024.18 Da for melanotan II). Vendor unwillingness to specify is itself the signal.

Pattern 2: The PT-141 versus melanotan II confusion.
PT-141 (bremelanotide) and melanotan II have very similar molecular weights (1025.18 Da versus 1024.18 Da — a difference of approximately 1 Da, reflecting a C-terminal carboxylic acid in PT-141 versus a C-terminal amide in melanotan II). Lower-precision mass spec analysis cannot reliably distinguish them. The compounds have different receptor selectivity (PT-141 more selective for MC4R) and different research applications. A vendor selling "PT-141" that is actually melanotan II is committing a substitution that requires high-precision mass spec to catch.

How to detect it: demand mass spec at sufficient precision to distinguish 1024 Da from 1025 Da. Higher-end labs report mass to one or two decimal places of accuracy. A "rounded" mass spec report that just says "approximately 1025 Da" is not enough resolution.

Pattern 3: Oral or topical melanotan.
Melanotan I and II are essentially never effective via oral or topical administration for systemic pigmentation effects. The peptide structure and size make oral and topical absorption minimal at concentrations that produce systemic melanocyte activation. Vendors selling oral melanotan tablets, sublingual melanotan, or topical melanotan creams are selling product that does not match what the published research has investigated. Whether the product contains the compound at all is a separate question from whether oral or topical administration produces meaningful systemic effects — the research suggests it does not.

How to detect it: just the existence of an oral or topical melanotan product is the signal. The compounds are not bioavailable enough by those routes for the form to be a credible research delivery method.

Pattern 4: Free GHK sold as GHK-Cu.
Some vendors sell uncomplexed GHK (the tripeptide alone) labeled as "GHK-Cu" with the implication that the buyer can add copper at reconstitution. This is not necessarily fraudulent if the vendor discloses it clearly — uncomplexed GHK + customer-added copper at reconstitution is a legitimate research approach with its own pros and cons. But vendors who do not clearly disclose that the product is uncomplexed and that the customer must add copper to obtain the bioactive species are being misleading.

How to detect it: mass spec on the COA. Free GHK is 340.38 Da. The GHK-Cu complex is approximately 403.93 Da. A vendor selling "GHK-Cu" with a mass spec value of 340 Da is selling uncomplexed GHK regardless of the label.

Pattern 5: Heavy metal contamination in low-grade copper sources.
Pre-complexed GHK-Cu products use copper as part of the active species. Lower-quality copper sources can contain trace contaminants — lead, arsenic, cadmium, other heavy metals — that should not be present in a research peptide product. Vendors not testing for or reporting heavy metal content cannot rule out contamination.

How to detect it: heavy metals testing should appear on the COA for any pre-complexed GHK-Cu product. Absence is a quality gap. The cost of the test is small enough that any serious vendor includes it.

Pattern 6: Overstated topical concentration claims.
Topical GHK-Cu products are sold across a wide range of marketed concentrations. Some products claim concentrations that do not match what the published research has shown to be effective; others claim concentrations that are higher than what is stable in the formulation provided. Without third-party assay of the actual product (not just label claims), the buyer cannot distinguish.

How to detect it: ask for the lot-specific concentration assay. Vendors with high-quality formulations and quality-control processes will be able to provide it. Vendors who cannot are providing label claims that are not independently verified.

Pattern 7: The "anti-aging miracle" overclaim.
Cosmetic peptides are particularly subject to overclaim because the cosmetic industry has a long history of marketing language that exceeds what the underlying science supports. GHK-Cu has real and documented effects but is not a "miracle" anti-aging compound that reverses years of damage in weeks. Melanotan compounds produce real pigmentation effects but are not without side effects. Hair-loss peptides have real research support but the published evidence is younger and thinner than the marketing typically conveys.

How to detect it: cross-check vendor claims against the published research. If the marketing claims substantially exceed what the literature supports, the vendor is overselling — and overselling on claims usually correlates with overselling on quality and provenance too.

Pattern 8: The "as effective as finasteride" hair loss overclaim.
Some hair-loss peptide vendors claim equivalent or superior effectiveness to finasteride or minoxidil based on small, preliminary, or unpublished studies. The published comparative research is much thinner than these claims suggest. The peptides may have legitimate research interest as adjunctive or alternative treatments, but framing them as drop-in replacements for established treatments is not supported by the current literature.

How to detect it: ask for the comparative research backing the claim. If the vendor cannot point to peer-reviewed published research with head-to-head comparison, the claim is marketing rather than science.

What to do if a suspect vendor was already used.
Document the COA received and the product behavior observed. If the product is topical, the perceived effectiveness is also an indirect quality signal — products with overstated concentrations or degraded actives produce smaller observed effects. Post specific findings on the platform with vendor name and product details. Community-sourced quality data is the strongest defense against overclaim and substitution patterns in this category.

If you are shopping for a vendor in this category and you are not sure how to evaluate the COA or the product specifications, post a redacted COA in the Quality and COA discussion thread and the community can help you read it.